Abstract:Background: Exocrine Pancreatic insufficiency (EPI) occurs following acute pancreatitis (AP) at variably reported rates and with unclear recovery timeline. The aim of this study was to establish the prevalence and predictors of EPI at 12 months after AP in a prospective cohort. Methods: In this prospective, multicentre, longitudinal cohort study, adult participants (≥18 years) admitted to the hospital with an AP attack (defined by Revised Atlanta Classification) were enrolled in a United States multi-centre longitudinal cohort (Sites: The Ohio State University, University of Pittsburgh, and Johns Hopkins University). Patients were excluded if they had pancreatic cancer, chronic pancreatitis, or malabsorptive disease (including previously diagnosed EPI). Participant data was obtained by interview and by review of the electronic medical record. EPI was assessed by stool fecal elastase (FE-1) levels collected at baseline, 3 months, and 12 months (primary endpoint). EPI was defined by FE-1 <200 μg/g; severe FE-1 level ≤100 μg/g; mild FE-1 101-200 μg/g. Multivariable logistic regression was used to identify predictors of EPI at 12 months. This study is registered with ClinicalTrials.gov, NCT03063398. Findings: EPI was observed in 29 (34.1%) of the 85 participants [44 (51.8%) male, mean age 54.7 ± 14.1 years] who provided stool samples at 12 months. For the study overall, participants were recruited between June 22, 2017 and October 18, 2021. A total of 5794 individuals were screened, 311 of whom were eligible for the study. 112 participants provided stool samples at baseline, 79 completed stool samples at 3 months, and 85 completed samples at 12 months. 64 participants included samples at all 3 timepoints. In univariable analysis, factors significantly associated with EPI at 12 months included recurrent (versus index) AP, pre-existing diabetes, alcohol, and idiopathic etiologies, and increasing severity of AP. In multivariable analysis, the odds of having EPI at 12 months increased 4-fold with idiopathic AP etiology (Odds Ratio 4.095, 95% Confidence Interval [CI] 1.418, 11.826), and 3-fold with moderately severe or severe AP (Odds Ratio 3.166, 95% CI 1.156, 8.670), and baseline diabetes mellitus (Odds Ratio 3.217, 95% CI 1.113, 9.298). Even individuals with an index mild attack of AP (n = 39) developed severe EPI at 12 months (prevalence 12.8%). Interpretation: EPI as diagnosed by FE-1 is present in over one third of prospectively assessed patients at 12 months post-AP. Since EPI develops in patients with mild AP, investigations are needed to understand the mechanisms of injury and identify methods for tailored screening. Funding: This study was supported by an Investigator Initiated Research Grant from AbbVie, Inc.

Apolipoprotein A2 isoforms associated with exocrine pancreatic insufficiency in early chronic pancreatitis

Abstract B007: Early detection and risk stratification of pancreatic cancer using apolipoprotein A2-isoforms as a blood biomarker

Elevated Serum Ferritin Levels Are Associated with Severity and Prognosis of Severe Acute Pancreatitis: a Preliminary Cohort Study

CA19‐9 and apolipoprotein‐A2 isoforms as detection markers for pancreatic cancer: a prospective evaluation

Elevated Serum HbA1c Level, Rather Than Previous History of Diabetes, Predicts the Disease Severity and Clinical Outcomes of Acute Pancreatitis

Clinical development of a blood biomarker using apolipoprotein-A2 isoforms for early detection of pancreatic cancer

Predictive Insights Into Exocrine Pancreatic Insufficiency in Chronic Pancreatitis and Autoimmune Pancreatitis

Serological Characteristics Of Autoimmune Pancreatitis And Its Differential Diagnosis From Pancreatic Cancer By Using A Combination Of Carbohydrate Antigen 19-9, Globulin, Eosinophils And Hemoglobin

Potential of Carbohydrate Antigen 19-9 and Serum Apolipoprotein A2-Isoforms in the Diagnosis of Stage 0 and IA Pancreatic Cancer

Pancreatic exocrine function and morphology following an episode of acute pancreatitis.

Noninvasive risk stratification of intraductal papillary mucinous neoplasia with malignant potential by serum apolipoprotein-A2-isoforms

ITRAQ-based Quantitative Proteomics Reveals Apolipoprotein A-I and Transferrin As Potential Serum Markers in CA19-9 Negative Pancreatic Ductal Adenocarcinoma

IDDF2019-ABS-0338 Serum Nutritional Markers for Assessment of Pancreatic Exocrine Insufficiency in Chronic Pancreatitis Patients

Comparison of pancreatic enzyme abnormalities and protease‐activated receptor‐2‐positive eosinophils in the duodenum of patients with functional dyspepsia‐irritable bowel syndrome overlap with functional dyspepsia alone in Asian populations

Circulating immune signatures in chronic pancreatitis with and without preceding acute pancreatitis: A pilot study

Serum levels of apolipoprotein A-I and high-density lipoprotein can predict organ failure in acute pancreatitis

Prevalence of exocrine pancreatic insufficiency at 12 months after acute pancreatitis: a prospective, multicentre, longitudinal cohort study

The Role of Adipokines in Chronic Pancreatitis. A Systematic Review and Meta-Analysis

Evaluation of Serum ATX and LPA As Potential Diagnostic Biomarkers in Patients with Pancreatic Cancer

Genotypes of carboxypeptidase A1 and gamma-glutamyltransferase 1 may be useful tools for the diagnosis and the predictor of worrisome features of intraductal papillary mucinous neoplasm in Japan

Postprocedure serum amylase or lipase levels predict postendoscopic retrograde cholangiopancreatography pancreatitis: Meta-analysis of diagnostic test accuracy studies and utility assessment